Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  GENE THERAPY
A Global Strategic Business Report

This report analyzes the Global market for Gene Therapy in Millions of US$. Annual forecasts are provided for the period 2007 through 2015. The report profiles 100 companies including many key and niche players worldwide such as AnGes MG Inc., Cell Genesys, GenVec, Genzyme Corporation, Introgen Therapeutics Inc., Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd., Targeted Genetics Corp., Transgene, Urigen Pharmaceuticals Inc., and Vical. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1127  PAGES:    293
PRICE:    $3950  DATE:       October 2008
COMPANIES:  100  MARKET DATA TABLES:   38
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  GENE THERAPY (Complete Report) Pages : 293   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3  
II. A GLOBAL MARKET REPORT60$3000
  1. Market Dynamics.....II-12 $400  
   Future – On a Promising Note.....II-1
Market Predictions Thrive On.....II-1
China – First to Hit the Market.....II-1
Counting on the Success Factors.....II-1
1$100
   Global Market Analysis.....II-2
Table 1: World Current & Future Market Analysis for Gene Therapy –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-2
1$300
  2. Key Issues/ Trends.....II-33 $300  
   Factors Influencing Gene Therapy Future Development.....II-3
Human Genome Analysis.....II-3
Gene Therapy - The Next Generation Cardiovascular Therapy.....II-3
Public Support for Gene Therapy.....II-3
RNAi Bode Bright Prospects.....II-3
Factors Hampering Market Growth.....II-3
Stringent Regulatory Laws in US and Europe Prolongs Gene Therapy Development.....II-3
1$100
   Identifying Genetic Fault.....II-4
Immune Response.....II-4
Delivering Genetic Materials into Patient Cells.....II-4
1$100
   Multigene Disorders.....II-5
Side Effects.....II-5
Push Towards Germline Gene Transfer.....II-5
Technical Limitations.....II-5
1$100
  3. The Global Landscape.....II-66 $700  
   Alliances and Acquisitions – Strategy to Success.....II-6
Patent Pooling: Yet Another Obstacle.....II-6
Commercialization: A Road Uphill.....II-6
1$100
   Time Line in Gene Therapy Drug Development.....II-7
Target Diseases and Players Involved.....II-7
Key Players by Application Area.....II-7
1$100
   Table 2: Gene Therapy Clinical Trials Worldwide (2007): Percentage Breakdown by Disease/ Application Area for Cancer, Heart Disease, Monogenic Diseases, Infectious Diseases and Others (includes corresponding Graph/Chart).....II-8

Table 3: Gene Therapy Clinical Trials Worldwide (2007): Percentage Breakdown by Gene Type Transferred for Antigen, Cytokine, Tumor Suppressor, Growth Factor, Suicide, Deficiency and Others (includes corresponding Graph/Chart).....II-8
1$300
   Table 4: Gene Therapy Clinical Trials Worldwide (2007): Percentage Breakdown by Vector Type for Adenovirus, Retrovirus, Naked/Plasmid DNA, Lipofection, Vaccinia Virus, Poxvirus, Adeno-associated Virus and Others (includes corresponding Graph/Chart).....II-9

Table 5: Gene Therapy Clinical Trials Worldwide (2007): A Split by Development Phase (includes corresponding Graph/Chart).....II-9

Table 6: Gene Therapy Clinical Trials (2007): Percentage Breakdown by Geographic Region for US, Europe, Canada, Japan and Rest of World (includes corresponding Graph/Chart).....II-9
1$300
   Various Gene Therapy Products Under Development (2007).....II-10
Gene Therapy Industry in Europe and the US – A Comparison.....II-10
2$200
  4. Review of Major Markets.....II-127 $600  
   United States.....II-12
Regulatory Environment.....II-12
Food and Drug Administration.....II-12
1$100
   IRB and IBC.....II-13
NIH.....II-13
1$100
   Europe.....II-14
Germany and UK- The Hub of European Gene Therapy Market.....II-14
1$100
   Table 7: Gene Therapy Clinical Trials in Europe (2007): Percentage Breakdown of Number of Trials by Country for UK, Germany, Switzerland, France, Belgium, Netherlands and Others (includes corresponding Graph/Chart).....II-15
Regulatory Environment.....II-15
Gene Therapy Advisory Committee.....II-15
1$300
   European Society of Gene and Cell Therapy (ESGCT).....II-16
Study of Regulatory Environment in Select European Countries.....II-16
United Kingdom.....II-16
Germany.....II-16
Italy.....II-16
Sweden.....II-16
1$100
   The Netherlands.....II-17
Switzerland.....II-17
Japan.....II-17
Asia-Pacific.....II-17
World's First Gene Therapy Medicine Approved in China.....II-17
1$100
   Prospects for Gendicine.....II-18
Competition.....II-18
Rest of World.....II-18
1$100
  5. Gene Therapy - An Insight.....II-194 $400  
   Molecular Basics – The Gene.....II-19
Genome – The Information Pool.....II-19
Functional cloning.....II-19
Random sequencing.....II-19
1$100
   Positional cloning......II-20
What is Gene Therapy?.....II-20
A Backdrop.....II-20
1990 Highlights - The Preliminary Gene Therapy Trial.....II-20
1995 Highlights.....II-20
2000 Highlights – Clinical Trials Reaches 400- Milestone.....II-20
1$100
   2004 Witnesses the First Gene Therapy Drug.....II-21
Classical Theory of Gene Therapy.....II-21
Ex-Vivo Approach of Gene Therapy.....II-21
In-vivo Approach of Gene Therapy.....II-21
Types of Gene Therapy.....II-21
Monogenic Gene Therapy.....II-21
1$100
   Suicide Gene Therapy.....II-22
Antisense Gene Therapy.....II-22
Various Approaches.....II-22
1$100
  6. Components of Gene Therapy.....II-234 $400  
   Vector.....II-23
Delivery Vehicles and Challenges in Use of Viral Vectors.....II-23
Gene Delivery – Without Virus.....II-23
1$100
   Non-Viral Products in Pipeline.....II-24
Well-known Delivery Approaches for Gene Therapy.....II-24
1$100
   Viral and Non-viral Vectors in Use.....II-25
Retroviruses.....II-25
Adenoviruses.....II-25
Adenoassociated viruses.....II-25
Herpes simplex viruses.....II-25
Lentiviruses.....II-25
Liposomes.....II-25
Viral Vectors by Companies involved.....II-25
1$100
   Gene Cassette.....II-26
Target cells.....II-26
Stem cells.....II-26
Differentiated cells.....II-26
The Disc: An Excellent Target for Gene Therapy.....II-26
1$100
  7. Review of Various Approaches.....II-272 $200  
   Antisense Technology.....II-27
Catalytic Ribozyme Technology.....II-27
Triple Helix DNA.....II-27
2$200
  8. Gene Therapy For Disease Treatment.....II-297 $500  
   Gene Therapy for Cancer Treatment.....II-29
Gene Transfer and Gene Therapeutic Concepts in Cancer.....II-29
1$100
   Competitive Landscape in Cancer Gene Therapy.....II-30
Gene Therapy Mechanism in Cancer.....II-30
1$100
   Advantages Over Chemotherapy.....II-31
Developments in Cancer Gene Therapy.....II-31
P53 Gene Therapy – A Novel Approach in Cancer Treatment.....II-31
1$100
   Gendicine – From Concept to Reality.....II-32
Vaccines.....II-32
Gene Therapy for Cardiovascular Disease.....II-32
Cardiovascular Gene Therapy Products under Trial.....II-32
1$100
   Gene Therapy for Cystic Fibrosis Disease.....II-33
Gene Therapy for Haemophilia B.....II-33
1$100
   Gene Therapy for HIV/AIDS.....II-34
Gene Therapy for Parkinson’s Disease.....II-34
The Disease.....II-34
1$100
   Therapy.....II-35
1$100
  9. Regulatory Environment.....II-361 $100  
   Gene therapy and Regulatory Environment.....II-36
Gene Patents - An Overview.....II-36
1$100
  10. Research and Development.....II-372 $200  
   Researchers Develop Synthetic Gene Vectors to Reduce Body Immune Responses.....II-37
Illumina Brings Digital Gene Expression Applications.....II-37
1$100
   MolMed Develops Gene Therapy Based Treatment for Skin Cancer.....II-38
Santaris Pharma Develops New Therapy to Lower Cholesterol Level.....II-38
Researchers Develop Gene Therapy for Severe Burns.....II-38
AMT Develops (AAV) Vector-Based Gene Therapy.....II-38
Ark Comes Up with New Gene Thearpy Delivery Technology.....II-38
1$100
  11. Recent Industry Activity.....II-3913 $800  
   International Consolidated to Acquire China Gene.....II-39
Ark Therapeutics to Acquire Lymphatix.....II-39
Oxford BioMedica Obtains Rights for RNAi Technology.....II-39
Gene Bridges Inks Licensing Agreement with Genencor.....II-39
1$100
   AMT Enters into R&D Agreement with NIH.....II-40
VGX Inks Supply Agreement with a U.K. Consortium.....II-40
Cardium Therapeutics Receives Fast Track Designation for Generx™.....II-40
Oxford Biomedica’s ProSavin Enters Phase I/II Trial.....II-40
Lentigen Acquires Gene Delivery Technology from Cell Genesys.....II-40
1$100
   VIRxSYS Acquires SMaRT™ RNA Technology.....II-41
Gene Logic Divests Genomics Assets.....II-41
Genzyme Inks Agreement with Ceregene.....II-41
Silence Therapeutics Extends Agreement with Quark.....II-41
1$100
   Benda Inks HIV Vaccine Joint Venture with DNAVEC.....II-42
Research Dynamics Bags Contract for Multicenter Clinical Study.....II-42
Thermo Fischer Collaborates with Lentigen to Develop Gene-Silencing Technology.....II-42
Fovea Enters into Collaboration with GENZYME Corporation.....II-42
1$100
   Oxford BioMedica Inks Licensing Agreement with Children’s Hospital.....II-43
Sigma and Oxford Sign Joint License Agreement for LentiVector Technology.....II-43
Benda Attains Additional Stake in SiBiono.....II-43
Oxford BioMedica Acquires Oxxon.....II-43
Oxford BioMedica and Sanofi-Aventis Agrees to Co-Develop and Market TroVax.....II-43
1$100
   Illumina Completes Acquisition of Solexa.....II-44
RheoGene Plans Merger with Intrexon.....II-44
Covalon Acquires Gene Therapy Technology from Perfusion.....II-44
Inovio Takes Over DNA Expression and Delivery Assets of Valentis.....II-44
1$100
   Mologen Inks Agreement with ONCO.....II-45
Aida Acquires Controlling Stake in Qiaer.....II-45
Neurologix Inks Licensing Agreement with Diamyd Medical’s Subsidiary.....II-45
Takara Inks Collaboration Agreement with Chinese Center for Disease Control.....II-45
JDRF Collaborates with Genzyme Corp and AGTC.....II-45
1$100
   Galapagos Collaborates with Arthrogen.....II-46
Genzyme Acquires Avigen’s Gene Therapy Assets.....II-46
Diamyd Acquires Nurel.....II-46
1$100
   Oxford BioMedica Accords with Sigma-Alrdrich.....II-47
Oxford BioMedica Inks Licensing Agreement with Pfizer.....II-47
genOway Acquires IngenKO Pty Ltd.....II-47
Crucell Strikes a Deal with Two Asian Firms.....II-47
Corautus’ VEGF-2 Gene Therapy Gains Recognition from US FDA.....II-47
ViroMed Ceases Development of Gene Therapy.....II-47
Corautus Genetics Pacts with CSEMC.....II-47
1$100
   Takara Bio Collaborates with Mie University.....II-48
Celladon Accords with V-Kardia.....II-48
Genzyme Acquires Ilex Oncology.....II-48
Genzyme and AGTC Form Collaboration.....II-48
Sanofi-Synthelabo Merges with Aventis.....II-48
Guidant Forms Collaboration with Columbia and Stony Brook.....II-48
1$100
   Louisiana and Bionomics Team-Up.....II-49
Avigen Receives FDA Clearance to Commence Phase I/II Clinical Trial of Av201.....II-49
Oxford BioMedica and Viragen Enters into Licensing Agreement.....II-49
Oxford BioMedica Signs Licensing Agreement with Merck.....II-49
Avigen Starts Gene Therapy Trial for Parkinson’s Disease .....II-49
1$100
   Oxford BioMedica Acquires Chiron Patents.....II-50
UA duo Establishes Gene-therapy Firm.....II-50
SiBiono Commences Construction of Gene Therapy Facility.....II-50
Avigen Receives FDA Approval for Clinical Trial of AV201.....II-50
UK GTAC Approves Clinical Trial.....II-50
CYGEE Bags patent Approval for Novel Gene Therapy Technology.....II-50
1$100
   Mirus Bio Receives $1.26 million SBIR Grant.....II-51
CEGE Trials Novel Gene Therapy.....II-51
Avigen Suspends Haemophilia Gene Therapy Trials.....II-51
1$100
  12. Strategic Corporate Developments (2000-2003).....II-525 $500  
   Oxford BioMedica and RPR Enters into Licensing Agreement.....II-52
Schering AG Acquires Collateral Therapeutics.....II-52
MolMed SpA Buys Rights to RectroNectin.....II-52
Avigen Receives US FDA Approval.....II-52
Targeted Genetics Receives Patents.....II-52
1$100
   Enzo Biochem Conducts Phase I Studies Related to HIV Treatment.....II-53
Eurogene Acquires Oy Quattrogene.....II-53
Cardion AG Acquires Tolerance Pharmaceuticals.....II-53
Aventis Restructures Gene-Therapy Alliance with Introgen.....II-53
Boehringer Ingelheim Austria GmbH Inks Agreement with BIA Separations.....II-53
Cell Genesys Establishes New Subsidiary.....II-53
1$100
   Chiron Divests Gene Therapy Manufacturing Facility.....II-54
ViroMed Conducts Clinical Trials on Gene Therapy Drug.....II-54
EG009 Gene Therapy Doubles Survival Rate of Malignant Glioma Patients in Phase I/II
  Clinical Trials.....II-54
Genteric Receives Patent for Insulin Gene Pill System.....II-54
Bayer Corp. Receives Marketing and Distribution Rights to Coagulin-B.....II-54
Avigen Receives Patent for Parkinson’s Disease Gene Therapy.....II-54
Aventis Acquires License form Electrofect.....II-54
1$100
   DeveloGen Acquires Hepavec.....II-55
Targeted Genetics Acquires Genovo Inc.....II-55
GenStar Acquires Allegro Inc.....II-55
Argonex and Rohm & Haas Company Enter into a Joint Venture.....II-55
Nexell Therapeutics and Takara Shuzo Join Forces.....II-55
BTG International Inks Licensing Agreement with Avigen.....II-55
1$100
   Oxford BioMedica Awarded US Patens Concerning Retroviral And Lentiviral
  Systems.....II-56
Genteric Receives Gene Therapy Patent.....II-56
GenVec Granted Broad Gene Therapy Patent.....II-56
1$100
  13. Focus on Key Players.....II-574 $400  
   AnGes MG Inc (Japan).....II-57
Cell Genesys (US).....II-57
GenVec (US).....II-57
1$100
   Genzyme Corporation (US).....II-58
Introgen Therapeutics Inc (US).....II-58
Oxford BioMedica (UK).....II-58
1$100
   Shenzhen SiBiono GeneTech Co., Ltd (China).....II-59
Targeted Genetics Corp (US).....II-59
1$100
   Transgene (France).....II-60
Urigen Pharmaceuticals Inc. (US).....II-60
Vical, Inc. (US).....II-60
1$100
III. COMPETITIVE LANDSCAPE 224$995
  
Total Companies Profiled: 100 (including Divisions/Subsidiaries - 105 )

Region/Country                 Players


The United States                 64   
Canada                             2
Japan                              2
Europe                            31
     France                        4
     Germany                       7
     The United Kingdom            9
     Italy                         2
     Rest of Europe                9
Asia-Pacific (Excluding Japan)     6
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.